Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
From BioSpace · · 25 min
This plays from the publisher's own server. We do not host a copy.
Description
Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide (https://www.biospace.com/drug-development/ada-lilly-sets-new-record-in-weight-loss-olympics-with-next-gen-asset)—not just for weight loss but also for other indications (https://www.biospace.com/drug-development/ada-lillys-weight-loss-mastery-shows-benefits-in-menopause-sleep-apnea-more).
Obesity rival Novo Nordisk, meanwhile, held a dinner, (https://www.biospace.com/drug-development/ada-novo-boasts-deep-pipeline-breadth-of-assets-after-analysts-award-lilly-weight-loss-gold) during which executives may have convinced analysts that the company is turning a corner after a rough couple of years.
Also check out ADA updates from Roche (https://www.biospace.com/drug-development/ada-obesity-partners-zealand-and-roche-aim-for-weight-loss-sweet-spot-with-amylin-agonist) and partner Zealand Pharma, Boehringer Ingleheim (https://www.biospace.com/drug-development/boehringer-leans-on-fat-mass-benefits-as-obesity-bet-delivers-less-competitive-weight-reduction), Pfizer (https://www.biospace.com/drug-development/ada-metsera-asset-data-support-pfizers-entry-point-into-obesity-market) (touting results from its Metsera buy), AstraZeneca (https://www.biospace.com/drug-development/ada-astrazeneca-hands-structure-a-win-with-relatively-underwhelming-glp-1-pill-data), Kailera Therapeutics (https://www.biospace.com/business/ada-kailera-back-at-work-after-record-breaking-ipo-with-china-data-in-hand) and more (https://www.biospace.com/american-diabetes-association-ada).
Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition (https://www.biospace.com/deals/gsk-pays-10-6b-for-cancer-biotech-nuvalent-in-industrys-second-biggest-buy-of-the-year) of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio (https://www.biospace.com/deals/j-j-glows-with-1b-buyout-of-firefly-and-its-degrader-platform-tech) for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash.
At an FDA listening meeting last week on the Commissioner’s National Priority Voucher program, the agency heard multiple calls to pause it (https://www.biospace.com/fda/stakeholders-want-makarys-voucher-program-paused-calls-for-fda-independence). Confusion also still persists around all of the new rare disease pathways (https://www.biospace.com/fda/busy-fda-gives-rare-disease-sector-complementary-pathways-unanswered-questions), including the new plausible mechanism framework (https://www.biospace.com/fda/post-makary-new-rare-disease-framework-faces-fresh-uncertainty).